CHF Solutions, Inc. To Announce Third Quarter 2019 Financial Results and Corporate Update on November 5, 2019
October 29 2019 - 8:00AM
CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its third
quarter 2019 financial results will be released on Tuesday,
November 5, 2019. The company will host a conference call and
webcast at 9:00 AM ET that morning, during which management will
discuss the company's financial results and provide a general
business overview.
To access the live webcast, please visit the Investors page of
the CHF Solutions website at http://ir.chf-solutions.com or access
the webcast directly at http://ir.chf-solutions.com/events.
Alternatively, you may access the live conference call by dialing
(877) 303-9826 (U.S.) or (224) 357-2194 (international) and using
conference ID: 5258206. An audio archive of the webcast will
be available following the call on the Investor page at
http://ir.chf-solutions.com/events.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company
dedicated to changing the lives of patients suffering from fluid
overload through science, collaboration, and innovative. The
company is focused on developing, manufacturing and commercializing
the Aquadex FlexFlow system for aquapheresis therapy. CHF Solutions
is a Delaware corporation headquartered in Minneapolis, Minnesota
with wholly owned subsidiaries in Australia and Ireland. The
company has been listed on the Nasdaq Capital Market since February
2012.
About Aquadex FlexFlow® System
The Aquadex FlexFlow system is a clinically proven therapy that
provides a safe, effective, and predictable method of removing
excess fluid from patients suffering from fluid overload. The
Aquadex FlexFlow system is indicated for temporary (up to eight
hours) ultrafiltration treatment of patients with fluid overload
who have failed diuretic therapy, and for extended (longer than 8
hours) ultrafiltration treatment of patients with fluid overload
who have failed diuretic therapy and require hospitalization. The
company has submitted an application to the FDA requesting a
modification to the 510(k) clearance for the Aquadex FlexFlow
system to include pediatric patients above 20kg. All treatments
must be administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies.
CONTACTS:
INVESTORS:
Claudia Napal DraytonChief Financial Officer, CHF Solutions,
Inc.952-345-4205ir@chf-solutions.com-Or-
Bret ShapiroManaging Partner, CORE
IR516-222-2560brets@coreir.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024